Evidence map›Paper›PMID 35846309›Full record

ArticleFrontiers in endocrinology2022

Exploration of Noninvasive Detection of Advanced Glycation End Products in the Lens to Screen for Diabetic Kidney Disease.

Xue-Meng Zhang, Yuan Gao, Meng-Xue Yang, Xiao-Di Zheng, Rui Zhang, Yue-Yue Wu, Miao Zeng, Qian Yang, Zhi-Yan Yu, Jun Liu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Xue-Meng ZhangDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Yuan GaoGeneral Practice Clinic, Pujiang Community Health Service Center in Minhang District, Shanghai, China.
Meng-Xue YangDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Xiao-Di ZhengDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Rui ZhangDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Yue-Yue WuDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Miao ZengDepartment of Infectious Diseases, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Qian YangDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Zhi-Yan YuDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Jun LiuDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Bing-Bing ZhaDepartment of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Bo YangDepartment of Endocrinology, Affiliated hospital of Zunyi Medical University, Zunyi, China.
Fudan University · CNZunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is a complication of diabetes, which is the most common cause of end-stage renal disease (dialysis). DKD has a high mortality rate, and only early detection can nip this disease in the bud. Advanced glycation end products (AGEs)are generally believed to be involved in the occurrence of DKD. Studies have shown that the lens AGEs fluorescence for noninvasive detection has high consistency with the gold standard OGTT, has high sensitivity and specificity, and could be used as a practical tool for the early screening of type 2 diabetes mellitus (T2DM).Therefore, we speculated that the noninvasive lens AGEs fluorescence detection method can be used to predict the occurrence of DKD. This study detected levels of AGEs in multiple cellular and tissues and analyzed the relationships between AGEs and lens, eyeballs, peripheral blood mononuclear cell (PBMC), serum, and kidney. Additionally, we examined the possible role of lens AGEs fluorescence in DKD screening. Our preexperimental study found that lens AGE levels in patients with T2DM were positively correlated with PBM and serum AGE levels. Lens AGE levels in patients with T2DM were negatively correlated with eGFR and positively correlated with urinary ACR. The animal and cell experiments showed that the AGE levels in the eyeballs of DM mice were also positively correlated with those in the serum and kidney. To increase the reliability of the experiment, we increased the sample size. In our results, lens AGEs levels were positively correlated with the occurrence of DKD, and the incidence of DKD in the high lens AGEs group was 2.739 times that in the low lens AGEs group. The receiver operating characteristic (ROC) curves showed that patients with T2DM with a lens AGEs value ≥ 0.306 were likely to have DKD. The area under the ROC curve of the noninvasive technique for identifying DKD was 0.757 (95% Cl: 0.677-0.838, p<0.001), and the sensitivity and specificity were 70.0% and 78.7%, respectively. These results suggest that noninvasive lens AGEs detection technology has certain clinical value in diagnosing whether patients with T2DM have DKD.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesAnimalsGlycation End Products, AdvancedLeukocytes, MononuclearMiceReproducibility of ResultsGlycation End Products, Advancedadvanced glycation end products (AGEs)diabetic nephropathylensnoninvasive technologytype 2 diabetes mellitus

Identifiers

PMID35846309
PMCPMC9278348
OpenAlexW4283698135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.